Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

BackgroundRespiratory syncytial virus (RSV) is a leading cause of acute respiratory infections and hospitalisations in infants (age < 1 year) and young children. Little is known on RSV epidemiology and related inpatient healthcare resource use (HCRU) in Switzerland.AimTo explore RSV-related hospitalisations, inpatient HCRU and medical costs in all age groups, and risk factors for infant hospitalisations in Switzerland.MethodsWe used national hospital registry data from 2003 to 2021 identifying RSV cases with ICD-10-GM codes, and described demographic characteristics, HCRU and associated medical costs of RSV inpatients. The effect of risk factors on infant hospitalisation was estimated with logistic regression.ResultsWe observed a general increase and biannual pattern in RSV hospitalisations between 2003/04 and 2018/19, with 3,575 hospitalisations in 2018/19 and 2,487 in 2019/20 before numbers declined in 2020/21 (n = 902). Around two thirds of all hospitalisations occurred in infants. Mean (median) age was 118 (85) days in hospitalised infants and 74 (77) years in hospitalised adult patients (> 18 years); 7.2% of cases required intensive care unit stay. Mean inpatient medical costs were estimated at EUR 8,046. Most (90.8%) hospitalised infants with RSV were born after 35 weeks of gestation without bronchopulmonary dysplasia or congenital heart disease. Low birth weight, gestational age and congenital disorders were associated with a higher risk for hospitalisation.ConclusionsRSV leads to a substantial number of hospitalisations and peaks in hospital capacity utilisation. Measures to protect all infants from an RSV hospitalisation are essential in addressing this public health challenge.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11484346PMC
http://dx.doi.org/10.2807/1560-7917.ES.2024.29.39.2400119DOI Listing

Publication Analysis

Top Keywords

syncytial virus
8
virus rsv
8
infants rsv
8
inpatient burden
4
burden respiratory
4
respiratory syncytial
4
rsv
4
rsv switzerland
4
switzerland 2003
4
2003 2021
4

Similar Publications

Background: Respiratory infections significantly impact older adults in Latin America, highlighting the need for regionally adapted consensus-based vaccination recommendations to guide preventive strategies. This study aimed to develop a consensus among Latin American experts on vaccination against respiratory diseases in older adults in the region, including influenza, Streptococcus pneumoniae pneumonia, COVID-19, respiratory syncytial virus (RSV), and pertussis.

Methods: A two-round Delphi methodology was employed, involving 35 specialists from various medical fields.

View Article and Find Full Text PDF

Respiratory syncytial virus (RSV) is a major pathogen causing acute respiratory infections, and the RSV fusion glycoprotein (F) has been identified as a key target for developing small-molecule inhibitors. Based on our prior identification of lonafarnib as an F protein inhibitor, medicinal chemistry efforts led to the development of , which exhibits significantly enhanced potency against both laboratory and clinical RSV isolates in cellular assays. Time-of-addition and SPR assays indicate that inhibits viral entry by targeting the RSV F protein, but has farnesyltransferase-independent antiviral efficacy.

View Article and Find Full Text PDF

Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory diseases in children, especially in infants. The immune responses induced by RSV infection are a fairly complex process that can contribute significantly to disease severity. Despite decades of research on RSV, many immune mechanisms remain to be explored.

View Article and Find Full Text PDF

Background: The long-acting monoclonal antibody nirsevimab and respiratory syncytial virus (RSV) vaccines became available for prevention of severe RSV-associated disease in 2023. While clinical trials showed good efficacy and safety, their restrictive inclusion criteria, small sample sizes and short follow-up limit generalisability. We aimed to summarise real-world evidence on the effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults.

View Article and Find Full Text PDF

Reducing invasive RSV diagnostic testing with machine learning: A retrospective validation study.

J Infect Public Health

September 2025

Graduate School of Media and Governance, Keio University, 5322, Endo, Fujisawa, Kanagawa 252-0882, Japan. Electronic address:

Objective: To evaluate whether a machine learning (ML) based screening algorithm can optimize respiratory syncytial virus (RSV) testing while maintaining high diagnostic accuracy in pediatric patients.

Study Design: We conducted a retrospective analysis of pediatric patients under 2 years old who presented with respiratory infection symptoms and received RSV testing at Yokohama Municipal Citizen's Hospital (2009-2015). The cohort was divided into training (2009-2013; n = 3587) and validation (2014-2015; n = 587) sets.

View Article and Find Full Text PDF